Retrospective cohort using US and German claims/EHR data to describe treatment patterns after vantrelimab progression.
Budget vs actual spend
$310k
of $1.4M planned (21%)
Spend is in line with or behind elapsed time. Elapsed: 41%.
Late-by counts days between due date and completion, or due date and today for open milestones.
| Milestone | Due | Completed | Status | Timing | Late by | Evidence |
|---|---|---|---|---|---|---|
| Protocol synopsis approved | 15 Apr 2026 | 20 Apr 2026 | Completed | Completed late | 5 d | — |
| Governance review | 30 Jun 2026 | 14 Jul 2026 | Completed | Completed late | 14 d | Delayed 2 weeks; committee capacity |
| Contract executed with data partner | 31 Aug 2026 | — | Blocked | Overdue | 15 d | Data-licensing terms unresolved |
| First data cut | 28 Feb 2027 | — | Not started | Upcoming | — | — |
Insights routed to this initiative.
No insights are linked to this initiative.
Actions whose result record is this initiative.
No actions reference this initiative as their result.
SEQUENCE-RW data-licensing negotiation fails, leaving the sequencing evidence gap open at EU launch.
P 4 × I 4 = 16 · Evidence generation · Dr. Nikolai Petrov · due 30 Sept 2026
SEQUENCE-RW RWE cohort depends on Data-licensing clause decision (Internal)
Due 30 Sept 2026 · if delayed: First data cut slips past EU launch
Accept data-partner secondary-use clause for SEQUENCE-RW
Owner Dr. Nikolai Petrov · approvers Dr. Helen Okafor, Oliver Brandt · needs leadership
Same objective (SO-VTX-02)
Same objective (SO-VTX-02)
Same objective (SO-VTX-02)
No tasks are linked to this initiative
| Timestamp | Action | User | Field | Change | Reason | Source |
|---|---|---|---|---|---|---|
| 09 Sept 2026, 11:02 UTC | Update | MTMei Tanaka | topics | In progress → Reviewed | — | UI · AUD-002075 |
| 07 Sept 2026, 06:58 UTC | Update | GNGrace Nakamura | summary | Planned → Reviewed | — | Integration · AUD-002143 |
Data lineage